A strategic webinar on engineering and automating cryogenic storage systems to reduce quality risk, improve scalability, and support commercial readiness in cell and gene therapy manufacturing.
BioFabUSA will exhibit and present at DMC 2026, sharing how scalable biomanufacturing can strengthen U.S. defense capabilities and support resilient manufacturing systems.
ARMI will attend RAPID + TCT 2026 to explore the intersection of additive manufacturing and biomanufacturing, driving innovation in regenerative healthcare solutions.
ARMI will attend SynBioBeta 2026, highlighting the intersection of synthetic biology and regenerative manufacturing, with Dean Kamen featured among key innovators.
BioFabUSA, a program of ARMI, is a public-private partnership with more than 170 members, including companies, academic institutions and not-for profit organizations.
